| First Author | Kryczek I | Year | 2009 |
| Journal | Blood | Volume | 114 |
| Issue | 2 | Pages | 357-9 |
| PubMed ID | 19289853 | Mgi Jnum | J:150775 |
| Mgi Id | MGI:3851683 | Doi | 10.1182/blood-2008-09-177360 |
| Citation | Kryczek I, et al. (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114(2):357-9 |
| abstractText | It has been reported that ectopically expressed interleukin-17 (IL-17) in tumor cells suppresses tumor progression through enhanced antitumor immunity in immune competent mice or promote tumor progression through an increase in inflammatory angiogenesis in immune-deficient mice. The role of endogenous IL-17 in tumor immunity remains undefined. Here we showed that tumor growth and lung metastasis were enhanced in IL-17-deficient mice, associated with decreased interferon-gamma(+) natural killer cells and tumor specific interferon-gamma(+) T cells in the tumor draining lymph nodes and tumors. Together with the published data showing that in vitro transforming growth factor-beta and IL-6-polarized Th17 cells induce tumor regression, our work supports the notion that endogenous IL-17 or/and Th17 cells may play a protective role in tumor immunity. |
